 |
Research |
Our growing pipeline includes novel investigational medications for the potential treatment of HIV/AIDS, liver disease and cardiovascular and respiratory diseases.
|
At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs currently focus on therapeutics for the potential treatment of HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. Cayston
Potential Indication: Cystic Fibrosis Phase III
Ambrisentan (endothelin receptor antagonist)
Potential Indication: Idiopathic Pulmonary Fibrosis Phase III
Truvada/TMC 278 Fixed-dose Regimen (NNRTI)
Potential Indication: HIV/AIDS Phase III
Elvitegravir (integrase inhibitor)
Potential Indication: HIV/AIDS Phase III
Integrase Fixed-dose Regimen "Quad" (elvitegravir/FTC/TDF/GS 9350)
Potential Indication: HIV/AIDS Phase II
GS 9350 (PK enhancer)
Potential Indication: HIV/AIDS Phase II
GS 9450 (caspase inhibitor)
Potential Indication: Hepatitis C/Fibrosis Phase II
GS 9450 (caspase inhibitor)
Potential Indication: Nonalcoholic Steatohepatitis Phase II
GS 9190 (polymerase inhibitor)
Potential Indication: Hepatitis C Phase II
Cicletanine (antihypertensive)
Potential Indication: Pulmonary Arterial Hypertension Phase II
Cayston
Potential Indication: Bronchiectasis Phase II
GS 9310/11 (inhaled fosfomycin/tobramycin)
Potential Indication: Cystic Fibrosis Phase II
GS 9256 (protease inhibitor)
Potential Indication: Hepatitis C Phase I
GS 9411 (epithelial sodium channel blocker)
Potential Indication: Cystic Fibrosis Phase I
GS 6201 (A2B adenosine antagonist)
Potential Indication: Pulmonary Diseases Phase I
GS 9667 (partial A1 adenosine antogonist)
Potential Indication: Diabetes Phase I
Ranolazine (late sodium channel inhibitor)
Potential Indication: Diastolic Heart Failure Phase I
|